产品描述
| 溶解性 | Soluble in DMSO (>25 mg/ml), cold pyridine, dimethylformamide, dioxane, Acetone, Butyl Acetate, Ethanol (≥2 mg/ml), Ethyl Acetate, Methanol, water (<1 mg/mL ), and 45% (w/v) aq 2-hydroxypropyl-β-cyclodextrin (0.6 mg/mL). |
| 应用 | A selective inhibitor of TNF alpha biosynthesis shown to have immunomodulatory and antiangeogenic activity. |
| 产品介绍 | Thalidomide作为一种镇静药，免疫调节剂，用于治疗许多癌症的症状。Thalidomide抑制E3泛素连接酶（一种CRBN-DDB1-Cul4A复合物）。 |
| 备注 | Thalidomide was introduced as a sedative drug, immunomodulatory agent and also is investigated for treating symptoms of many cancers. Thalidomide inhibits an E3 ubiquitin ligase, which is a CRBN-DDB1-Cul4A complex. |
| 生化机理 | Thalidomide was commonly used therapeutically in the late 1950’s, however, it was withdrawn from the market when it was discovered to cause birth defects. More recent research has found Thalidomide to affect key biochemical pathways yielding antiangiogenic and immunomodulatory activities. This compound has been shown to: selectively inhibit TNF α (tumor necrosis factor-α) biosynthesis and basic fibroblast growth factor (bFGF)-induced angiogenesis, induce apoptosis in human monocytes via a cytochrome c-dependent pathway, and to inhibit HIV-1 replication in a monocytoid (U1) line. These new found uses make Thalidomide an extremely valuable research tool. |
| 别名 | (±)-沙利度胺;N-(2,6-二氧-3-哌啶基)邻苯二甲酰亚胺;沙利度胺; 酞咪哌啶酮; N-(2,6-二氧代-3-哌啶基)-邻苯二甲酰亚胺;(±)-2-(2,6-Dioxo-3-piperidinyl)-1H-isoindole-1,3(2H)-dione;N-(2,6-Dioxo-3-piperidinyl)phthalimide;(±)-Thalidomide |
